Thalassemia carrier in pregnancy: what comes next?

What does the evidence say about thalassemia carrier status in pregnancy?

1. Alpha-thalassemia findings range from silent carrier status to more substantial disease. Reproductive risk depends on the number and arrangement of affected alpha-globin genes and the other parent's results. The word trait on its own may not provide enough information for a precise risk assessment. 1
2. A person with one beta-globin gene variant may have few symptoms or mild anemia, often called beta-thalassemia minor. This differs from the more severe forms of beta-thalassemia. The particular variant and the partner's hemoglobin findings are important in reproductive counseling. 2
3. NHLBI describes blood counts, hemoglobin testing, and genetic testing as tools for clarifying thalassemia. Small red blood cells or mild anemia can prompt further assessment. Ask which tests establish the actual finding and whether another contributor to anemia also needs evaluation. 3
4. NHLBI recommends discussing inherited risk and partner screening before conception when possible. If pregnancy has already begun, the same information can guide timely counseling and discussion of prenatal testing. Recommendations for severe, transfusion-dependent disease should not automatically be applied to an otherwise healthy carrier. 4
5. Carrier screening assesses the possibility of an inherited condition; it does not itself establish whether a fetus has that condition. When both parents have relevant findings, genetic counseling can explain the available choices. Screening is voluntary, and the decision should reflect informed preferences. 5

When should thalassemia carrier results be reviewed?

• First trimester. Before or early in pregnancy, obtain the exact result and discuss partner testing and genetic counseling.
• Second trimester. During pregnancy, review completed testing and the meaning and limits of any fetal testing options.
• Third trimester. Before birth, share confirmed family results with the infant's clinician and continue the agreed maternal blood-count follow-up.

Questions to discuss with your care team